Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

'Provocative' New Evidence Links Vitamin D And Other Nutrients To Heart Disease
Emerging research suggests that nutritional factors including vitamin D, magnesium, and others may influence the risk and progression of cardiovascular disease. The new data on nutrition and heart disease were the topic of a recent symposium and are summarized in the July issue of The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation (SSCI). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and biomedical intelligence for students, professionals, and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry.
generic viagra online
Excellent Preclinical Data On Novel Type Of Intranasal H5N1 Influenza Vaccine
Studies performed in three animal models confirmed the safety and intensive immunogenicity of a new type of intranasal H5N1 influenza vaccine, according to the latest preclinical study data announced today by the Vienna based firm, Avir Green Hills Biotechnology. The study data was just published in PloS One, the Public Library of Science.
News of the day
Senate Fiscal Year 2010 Spending Bill Excludes Abstinence-Only Education Funding, Needle Exchange Language
The Senate Appropriations Labor, HHS, Education and Related Agencies Subcommittee on Tuesday approved by voice vote its fiscal year 2010 spending bill draft, which excludes funding for abstinence-only sex education programs and, unlike the House bill, does not include language lifting the ban on the use of federal funding for needle exchange programs, CQ Today reports. According to the article, Committee Chair Tom Harkin (D-Iowa) "confirmed that the bill will not contain funding for abstinence-only education programs when the full committee marks it up on Thursday. Instead, the draft will contain funding for more comprehensive sex education, which can include teaching abstinence." Harkin also said that the Senate bill does not contain language lifting the ban on the needle exchange funding because that is "a matter for conference" (Wolfe, 7/28).
Diagnostics

Unlikely Treatment Identified By BrainCells Neurogenesis Platform Improved Clinical Outcomes In Patients Suffering From Depression

BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary platform technology to identify novel pathways for the treatment of central nervous system (CNS) diseases, announced results from the first clinical proof-of-concept study of BCI-952, a combination of low dose buspirone and melatonin, for the treatment of major depressive disorder (MDD). The data were presented at NCDEU 2009, a meeting co-sponsored by the National Institute of Mental Health and the American Society of Clinical Psychopharmacology. Neurogenesis is the process by which pre-existing stem cells in the hippocampus of the adult brain produce new brain cells, including neurons. "Our study results provide the first prospective clinical validation of neurogenesis as a target for the treatment of mood disorders like depression, in contrast to the traditional focus on affecting serotonin function for antidepressant drug development," said lead investigator Maurizio Fava, M.D., vice chair, department of psychiatry at Massachusetts General Hospital and professor of psychiatry at Harvard Medical School. "Researchers have speculated that the brain"s ability to grow new brain cells may have an impact on depression, and we now know that we can stimulate the natural process of neurogenesis with a positive clinical impact on depression symptoms." "BCI-952 was selected by our proprietary platform for the compound"s neurogenic properties," said Jim Schoeneck, chief executive officer of BrainCells Inc. "The platform was able to identify the pathway, ratio of drug and dosing that shaped the clinical trial protocol, directing the first rational approach to drug development in the area of psychiatry." The double blind, placebo-controlled, randomized study evaluated the efficacy of BCI-952 for the treatment of MDD in 142 patients over a six-week period. Patients were randomized into one of three arms, BCI-952 (n=67), buspirone (n=34) or placebo (n=33). Co-primary endpoints were the Clinical Global Impression-Improvement (CGI-I) and the Quick Inventory of Depressive Symptomatology (QIDS SR-16). Secondary endpoints included the CGI-S, IDSC30 and HAMA. The data presented at the NCDEU meeting focused on the MITT population using both the LOCF and MMRM analyses for the co-primary endpoints. The CGI-I at week six demonstrated improvement relative to placebo using the MITT LOCF, MITT MMRM. The mean CGI-I scores were statistically significant relative to placebo using the MITT MMRM (p=0.046).The responders analysis for CGI-I (SCORE About BrainCells Inc. BrainCells Inc. (BCI) is a drug discovery and development company leading the scientific research of neurogenesis by applying its robust and proprietary platform technology to identify novel pathways for small molecule therapeutics to treat various central nervous system (CNS) diseases. Neurogenesis is the process by which endogenous stem cells in the adult human brain produce new brain tissue, including neurons. With its predictive screening platform, BCI can direct the selection and development of neurogenic compounds, increasing the opportunity for successful clinical trials in a variety of indications. BrainCells Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009